Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes - Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline of GEMMs candidates for inflammatory bowel disease - - Financing includes new investors led by...

Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001 - Orally-administered Genetically Engineered Microbial Medicine (GEMM) was safe and well tolerated and demonstrated dose-dependent strain engraftment in healthy volunteers - - Results provide...

Novome Biotechnologies Appoints Dr. Lachy McLean as Chief Medical Officer SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today...